If you watched the drama in Washington last month, you may have come away with the impression that the American health care system is a hopeless mess. So it is surprising that across the continent from Washington, investors and technology entrepreneurs in Silicon Valley see the American health care system as the next great market for reform

Quick Read

A new paper in the latest issue of Health Affairs is worth a look. “Drugs Cleared Through The FDA’s Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process“

Quick Read

Nearly 8 in 10 Americans say President Donald Trump should be trying to make the health law work, according to poll conducted by the Kaiser Family Foundation

Quick Read

“The stress and overwhelming crushing defeat of these bills that would come in every week — it had an effect on our quality of life,” Chino says

Quick Read

Faced with competition, some pharmaceutical companies are cutting deals with insurance companies to favor their brand-name products over cheaper generics. Insurers pay less, but sometimes consumers pay more. Adderall XR, a drug to treat attention-deficit hyperactivity disorder, is a case in point

Quick Read

The US FDA currently forbids any use outside of a research setting. But recent history has shown that people who want access to such techniques “can find people willing to perform them in venues where they’re able to do so,” said Jeffrey Kahn, who directs Johns Hopkins University’s Berman Institute of Bioethics. “It will happen whether we discuss it or not, and we need to talk about these things before they happen, That’s now.”

Quick Read

In April, Gundy’s child, who is on private insurance, began getting the drug Spinraza, which costs $750,000 for the initial year of treatment. Chaffin’s child — a Medicaid enrollee — was not receiving the drug, as his state regulators debated whether to offer it to children like him who use ventilators to breathe

Quick Read

Imagine now, that in the future, being poor also meant you were more likely than others to suffer from major genetic disorders like cystic fibrosis, Tay–Sachs disease, and muscular dystrophy. That is a future, some experts fear, that may not be all that far off

Quick Read